RESUMO
The six (racemic or meso) isomers of 3,4-dimethyl-2,5-bis(3,4-dimethoxyphenyl)tetrahydrofuran and four corresponding desmethyl analogues were prepared and assayed as inhibitors of platelet activating factor (PAF) receptor binding to rabbit platelet plasma membranes. The inhibition by these isomers is stereodependent and varies with the gross shape of the molecules as determined by the molecular mechanics program MM2. The most potent PAF antagonist in this group of compounds is trans-2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-652,731, 14) with an IC50 of 0.02 microM.
Assuntos
Furanos/farmacologia , Extratos Vegetais/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Animais , Furanos/síntese química , Lignanas , Conformação Molecular , Extratos Vegetais/síntese química , Coelhos , Relação Estrutura-AtividadeRESUMO
(-)-trans-(2S,5S)-2-[3-[(2-Oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (10) is one of the most potent platelet-activating factor (PAF) antagonists in vitro and in vivo developed to date. This diaryltetrahydrofuran derivative evolved from modifications of MK 0287 which has been evaluated in clinical studies for asthma. Two structural modifications of MK 0287 were made: (1) elaboration of the 3'-[(hydroxyethyl)sulfonyl] group to a beta-keto propylsulfonyl, and (2) replacement of the 5'-methyl ether by a 3-hydroxypropyl ether. Compound 10 potently and specifically inhibits the binding of [3H]-C18-PAF to human platelet membranes (Ki 1.85 nM) and PMN membranes (Ki 2.89 nM). In vivo, 10 inhibits PAF-induced plasma extravasation and elevated N-acetyl-beta-D-glucosaminidase (NAGA) levels in male rats with ED50 values of 60 micrograms/kg, po and 4 micrograms/kg, iv respectively, and inhibits PAF-induced bronchoconstriction in guinea pigs with an ED50 value of 15 micrograms/kg after intraduodenal administration. Compound 15, a water-soluble phosphate ester prodrug derivative of 10 is at least equipotent to 10 in the in vivo models. Compound 19S, the primary and major metabolite of 10 and 15, is equipotent in in vitro and in vivo models.
Assuntos
Furanos/síntese química , Fator de Ativação de Plaquetas/antagonistas & inibidores , Pró-Fármacos/síntese química , Sulfonas/síntese química , Administração Oral , Animais , Furanos/química , Furanos/farmacologia , Cobaias , Humanos , Masculino , Inibidores da Agregação Plaquetária/farmacologia , Pró-Fármacos/química , Pró-Fármacos/farmacologia , Ratos , Solubilidade , Estereoisomerismo , Relação Estrutura-Atividade , Sulfonas/química , Sulfonas/farmacologiaRESUMO
Chemistry that allows selective modification of the carboxylic acid groups of the squalene synthase inhibitor zaragozic acid A (1) was developed and applied to the synthesis of compounds modified at the 3-,4-,5-,3,4-,3,5-, and 4,5-positions. A key step in this procedure is the selective debenzylation by transfer hydrogenolysis in the presence of other olefinic groups. These compounds were tested in the rat squalene synthase assay and in vivo mouse model. Modification at C3 retains significant enzyme potency and enhances oral activity, indicating that C3 is not essential for squalene synthase activity. Modification at C4 and C5 results in significant loss in enzyme activity. In contrast, substitution at C3 or C4 enhances in vivo activity. Furthermore, disubstitution at the C3 and C4 positions results in additive in vivo potency.
Assuntos
Compostos Bicíclicos Heterocíclicos com Pontes , Compostos Bicíclicos com Pontes/química , Ácidos Carboxílicos/química , Farnesil-Difosfato Farnesiltransferase/antagonistas & inibidores , Ácidos Tricarboxílicos/química , Animais , Compostos Bicíclicos com Pontes/farmacologia , Esterificação , Masculino , Camundongos , Microssomos Hepáticos/enzimologia , Estrutura Molecular , Ratos , Relação Estrutura-Atividade , Ácidos Tricarboxílicos/farmacologiaRESUMO
Epibatidine, an alkaloid isolated from skin of the poison frog, Epipedobates tricolor, has been shown to be a very potent analgesic with a non-opioid mechanism of action. We found that epibatidine was about 120 times more potent and has longer duration than nicotine in analgesia, which could be antagonized by pretreatment with mecamylamine. Furthermore, epibatidine competed with high affinity (IC50 = 70 pM, Ki = 43 pM) for [3H]cytisine binding in rat brain preparations. These results indicated that the analgesic activity of epibatidine is attributed to its unique property as the most potent nicotinic acetylcholine receptor agonist.
Assuntos
Analgésicos/farmacologia , Encéfalo/metabolismo , Compostos Bicíclicos Heterocíclicos com Pontes , Compostos Bicíclicos com Pontes/farmacologia , Piridinas/farmacologia , Receptores Nicotínicos/efeitos dos fármacos , Alcaloides/metabolismo , Analgésicos/metabolismo , Animais , Azocinas , Ligação Competitiva , Encéfalo/efeitos dos fármacos , Compostos Bicíclicos com Pontes/metabolismo , Interações Medicamentosas , Mecamilamina/farmacologia , Camundongos , Nicotina/metabolismo , Nicotina/farmacologia , Piridinas/metabolismo , Quinolizinas , Ratos , Receptores Nicotínicos/metabolismoRESUMO
Three TLC methods of qualitative screening of capsicum products are described. A procedure using a two-dimensional reversed phase system and bromination of the sample gave the greatest flexibility but required the longest time. A one-dimensional reversed phase system using silver ion to complex with the unsaturated components is also described. Polyamide plates using silver ion in the developing solvent gave the greatest speed of the three methods compared.
Assuntos
Capsaicina/análise , Cromatografia em Camada Fina/métodos , Ácidos Graxos Insaturados/análise , Bromo , Avaliação Pré-Clínica de Medicamentos , SolventesRESUMO
A new synthetic compound, L-652,731 (trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran), which has been demonstrated by Hwang et al. to be a potent and specific platelet-activating factor (PAF) receptor antagonist causes 100% inhibition of 1 microM PAF-induced neutrophil degranulation at 50 microM, but has no effect on neutrophil degranulation induced by precipitating immune complexes (323 micrograms/ml), fMet-Leu-Phe (10(-7) M), or the calcium ionophore A23187 (10(-5) M). Intravenous infusion of 1 mumol L-652,731 results in almost 100% inhibition of hypotension induced by PAF but not that induced by isoproterenol, histamine, bradykinin, or acetylcholine. With the use of this novel PAF receptor antagonist, the in vivo mediator role of PAF in the soluble immune complex-induced hypotension, extravasation, vascular lysosomal hydrolase secretion, and neutropenia in rats was determined. The hypotension, extravasation, and lysosomal hydrolase release induced by immune complex infusion take 2 to 10 min longer to occur than the same responses elicited by PAF infusion. The neutropenia response is immediate with both stimuli. L-652,731 when orally administered to rats (20 mg/kg, 1.5 hr before PAF infusion) inhibited PAF-induced hypotension (69%), extravasation (76%), vascular lysosomal hydrolase release (79%), and neutropenia (73%). The same L-652,731-dosing regimen inhibited immune complex-stimulated hypotension (87%), extravasation (77%), and vascular lysosomal hydrolase release (31%). The initial and complete neutropenia induced by immune complex infusion was not inhibited in L-652,731-pretreated rats, but the rate of return of neutrophils to the blood was faster in the latter rats. Rats with blocked circulation to the liver still exhibited extensive extravasation and vascular lysosomal hydrolase release in response to PAF, but there was no extravasation and greatly reduced hydrolase release in response to immune complexes. Thus PAF is indicated to be a major mediator of soluble immune complex-induced hypotension and vascular permeability and a minor mediator of immune complex-induced lysosomal hydrolase release in rats. PAF probably does not mediate the initial and complete neutropenia stimulated by immune complexes. The liver is probably the major site for PAF production in response to circulating immune complexes.
Assuntos
Anafilaxia/imunologia , Complexo Antígeno-Anticorpo/fisiologia , Furanos/farmacologia , Fator de Ativação de Plaquetas/fisiologia , Glicoproteínas da Membrana de Plaquetas , Receptores de Superfície Celular/efeitos dos fármacos , Receptores Acoplados a Proteínas G , Anafilaxia/enzimologia , Anafilaxia/fisiopatologia , Animais , Complexo Antígeno-Anticorpo/análise , Permeabilidade Capilar/efeitos dos fármacos , Feminino , Hidrolases/metabolismo , Hipotensão/fisiopatologia , Cinética , Fígado/fisiopatologia , Lisossomos/enzimologia , Neutropenia/fisiopatologia , Fator de Ativação de Plaquetas/metabolismo , Ratos , Ratos EndogâmicosRESUMO
Trans-2,5-bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L652, 731), a potent and specific receptor antagonist of platelet activating factor (PAF) (Hwang et al., J. Biol. Chem. 260: 15639-15645, 1985), potently inhibits several PAF-induced in vivo responses in rats. Intravenously and p.o. administered L-652,731 gave a dose-response inhibition of PAF-induced lysosomal hydrolase secretion and extravasation with ED50 values of 1 and 3 mg/kg, respectively. Inhibitions of 87% were achieved with 50 mg/kg p.o. After a single 5-mg/kg p.o. dose, L-652,731 achieved 50 to 60% inhibition of PAF-induced lysosomal hydrolase secretion and extravasation by 0.5 to 1.5 hr with near maximum inhibition lasting through 6 hr. A 20-mg/kg p.o. dose of L-652,731 inhibited PAF-induced leukopenia and neutropenia by 96 and 73%, respectively. The most substantial inhibitions of the extravasation and lysosomal hydrolase secretion induced by PAF or soluble immune complexes were achieved by p.o. L-652,731 (20 mg/kg) with moderate inhibition by dexamethasone and little or no inhibition by antagonists/inhibitors of histamine H1 or H2 or serotonin receptors or cyclooxygenase. Intravenous infusion of a 0.4 mg of L-652,731 bolus inhibited the hypotensive responses from subsequent PAF infusions by a maximum of 72% and with a half-life duration of action of 2.5 hr. Intravenous infusion of L-652,731 results in an immediate 87% reversal of the extreme hypotension induced by a previous endotoxin injection. Thus, with its good p.o. activity, long duration of action and specificity in inhibiting PAF-induced responses in vivo, L-652,731 is a very useful tool in determining the role of PAF in mediating different pathophysiological processes.
Assuntos
Furanos/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Acetilglucosaminidase/metabolismo , Animais , Pressão Sanguínea/efeitos dos fármacos , Endotoxinas/antagonistas & inibidores , Feminino , Hidrolases/metabolismo , Leucopenia/induzido quimicamente , Leucopenia/prevenção & controle , Lisossomos/enzimologia , Neutropenia/induzido quimicamente , Neutropenia/prevenção & controle , Ratos , Ratos EndogâmicosRESUMO
trans-2,5-Bis(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-652,731) is found to be a potent and orally active platelet activating factor (PAF)-specific and competitive receptor antagonist. It potently inhibits [3H]PAF (1 nM) binding to receptor sites on rabbit platelet membranes with an ED50 of 2 X 10(-8) M under the assay condition without the addition of mono- or divalent cations. In a comparative study, it is more potent than CV-3988, kadsurenone, and ginkgolide B as a receptor antagonist. The equilibrium dissociation constants (KB) of L-652,731 obtained either from the inhibition of receptor binding or from the inhibition of PAF-induced aggregation of gel-filtered rabbit platelet are 2.7 X 10(-8) and 2.1 X 10(-8) M, respectively. The agreement of these KB determinations based on receptor and cellular function suggests that L-652,731 does not inhibit other steps following PAF-receptor binding. L-652,731 does not antagonize the binding of several radioligands to their respective receptor. It shows no inhibitory effect on platelet aggregation induced by other aggregating agents including thrombin, collagen, A-23187, arachidonic acid, epinephrine, and ADP. L-652,731 is orally active; it inhibits PAF-induced rat cutaneous vascular permeability with an ED50 of 30 mg/kg orally. Significant inhibitory results of L-652,731 suggest that PAF may be partially involved in cutaneous vascular permeability induced by histamine and bradykinin.
Assuntos
Benzofuranos , Furanos/farmacologia , Lignanas , Éteres Fosfolipídicos , Fator de Ativação de Plaquetas/antagonistas & inibidores , Glicoproteínas da Membrana de Plaquetas , Receptores de Superfície Celular/metabolismo , Receptores Acoplados a Proteínas G , Animais , Benzopiranos/farmacologia , Plaquetas/análise , Bradicinina/farmacologia , Permeabilidade Capilar/efeitos dos fármacos , Fenômenos Químicos , Química , Relação Dose-Resposta a Droga , Histamina/farmacologia , Humanos , Magnésio/metabolismo , Matemática , Agregação Plaquetária/efeitos dos fármacos , Coelhos , Sódio/metabolismo , Tiazóis/farmacologiaRESUMO
The title compound, L-659,989, is a highly potent, competitive, and selective antagonist of the binding of [3H]PAF to its receptors in platelet membranes from rabbits and humans. It exhibits equilibrium inhibition constants for PAF binding of 1.1 nM (rabbit) to 9.0 nM (human), values that are at least 1-2 orders of magnitude lower than those of other PAF antagonists tested. L-659,989 potently inhibits PAF-induced aggregation of rabbit platelets and degranulation of rat (ED50 4.5 nM) and human (ED50 10 nM) neutrophils. L-659,989 inhibits PAF-induced extravasation and lysosomal enzyme release in rats, and is active orally in female rats (ED50 0.2 mg/kg) with an extraordinary oral duration of action of 12 to 16 hours at 1.0 mg/kg p.o.
Assuntos
Furanos/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Glicoproteínas da Membrana de Plaquetas , Receptores de Superfície Celular/efeitos dos fármacos , Receptores Acoplados a Proteínas G , Acetilglucosaminidase/sangue , Animais , Ligação Competitiva , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Bovinos , Membrana Celular/metabolismo , Grânulos Citoplasmáticos/efeitos dos fármacos , Feminino , Cobaias , Hematócrito , Humanos , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Neutrófilos/ultraestrutura , Agregação Plaquetária , Inibidores da Agregação Plaquetária , Coelhos , Ratos , Receptores de Superfície Celular/metabolismoRESUMO
5-n-Pentyl oxadiazole substituted benzenesulfonamide 8 is a potent and selective beta3 adrenergic receptor agonist (beta3 EC50 = 23 nM, beta1 IC50 = 3000 nM, beta2 IC50 = 3000 nM). The compound has high oral bioavailability in dogs (62%) and rats (36%) and is among the most orally bioavailable beta3 adrenergic receptor agonists reported to date.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/farmacologia , Agonistas Adrenérgicos beta/farmacocinética , Oxidiazóis/farmacologia , Oxidiazóis/farmacocinética , Administração Oral , Agonistas Adrenérgicos beta/administração & dosagem , Agonistas Adrenérgicos beta/química , Animais , Disponibilidade Biológica , Células CHO , Cricetinae , Cães , Desenho de Fármacos , Humanos , Estrutura Molecular , Oxidiazóis/administração & dosagem , Oxidiazóis/química , Ratos , Relação Estrutura-AtividadeRESUMO
Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta3 adrenergic receptor (AR) agonists. The 4-trifluormethoxy substituted 5-benzyl oxadiazole 5f has an EC50 of 8 nM in the beta3 AR agonist assay with 100-fold selectivity over beta1 and beta2 AR binding inhibition activity. Its oral bioavailability in dogs is 30 +/- 4%, with a half-life of 3.8 +/- 0.4 h. In the anesthetized rhesus, 5f evoked a dose-dependent glycerolemia (ED50Gly = 0.15 mg/kg). Under these conditions a heart rate increase of 15% was observed at a dose level of 10 mg/kg.